$13.65
4.96%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

uniQure N.V. Stock price

$13.00
-1.53 10.53% 1M
+6.72 107.01% 6M
-4.66 26.39% YTD
+8.33 178.37% 1Y
-4.32 24.94% 3Y
-42.95 76.77% 5Y
-13.97 51.80% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+3.61 38.45%
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

Key metrics

Market capitalization $703.00m
Enterprise Value $836.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 30.84
P/S ratio (TTM) P/S ratio 25.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 71.17%
Revenue (TTM) Revenue $27.12m
EBIT (operating result TTM) EBIT $-192.12m
Free Cash Flow (TTM) Free Cash Flow $-183.52m
Cash position $367.52m
EPS (TTM) EPS $-4.93
P/E forward negative
P/S forward 17.71
EV/Sales forward 21.07
Short interest 8.20%
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a uniQure N.V. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a uniQure N.V. forecast:

Buy
86%
Hold
14%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
27 27
71% 71%
100%
- Direct Costs 31 31
21% 21%
114%
-3.85 -3.85
60% 60%
-14%
- Selling and Administrative Expenses 33 33
34% 34%
123%
- Research and Development Expense 142 142
4% 4%
524%
-179 -179
14% 14%
-662%
- Depreciation and Amortization 13 13
6% 6%
47%
EBIT (Operating Income) EBIT -192 -192
13% 13%
-708%
Net Profit -240 -240
22% 22%
-883%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Positive
Seeking Alpha
about 13 hours ago
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-tim...
Neutral
Seeking Alpha
2 days ago
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact.
Neutral
GlobeNewsWire
4 days ago
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 209
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today